May 07, 2020
Applied BioMath, LLC Provides Systems Pharmacology Model to Support Fibrinolytic Therapy for Refractory COVID-19 Acute Respiratory Distress Syndrome
Mar 22, 2020
Liminal BioSciences comments on Coronavirus (COVID-19)
May 22, 2019
Prometic presents new PBI-4050 and Ryplazim(TM) (plasminogen) data on lung fibrosis at the 2019 ATS Conference
Apr 25, 2019
Now Available From Aniara Diagnostica, Aprotinin a Lyophilized Powder From Bovine Lung
Feb 28, 2019
American Regent Announces the Re-Introduction of Aminocaproic Acid Injection, USP; AP Rated and Therapeutically Equivalent to Amicar®*(1)
Oct 16, 2018
Prometic announces positive feedback from FDA Type-C meeting on Ryplazim(TM) (plasminogen) BLA
Jan 09, 2018
New Absorbable Adjunctive Hemostat From Ethicon Helps Surgeons Control Disruptive Bleeding More Efficiently
Dec 18, 2017
Prometic's Plasminogen (Ryplazim(TM)) granted orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF)
Dec 06, 2017
Pivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for Hematology
Nov 01, 2017
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation
Oct 26, 2017
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer Phase 2 clinical trial
Oct 19, 2017
Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim(TM))
Oct 13, 2017
Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim(TM))
Sep 18, 2017
TSI Completes Phase 1 Clinical Trial of Novel Clot-dissolving Therapy, TS01
Aug 29, 2017
Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy